Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14129
Abstract: The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA)… read more here.
Keywords: bleeding episodes; patients anti; prevention bleeding; anti fviii ... See more keywords
Evaluation of anti‐factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14202
Abstract: Bleeding episodes in patients who have haemophilia A (HA), a hereditary bleeding disorder caused by a deficiency in factor VIII (FVIII), are treated or prophylactically prevented with infusions of exogenous FVIII. Neutralizing antibodies, referred to… read more here.
Keywords: patients haemophilia; immune tolerance; factor viii; induction therapy ... See more keywords
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14213
Abstract: Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A with and without inhibitors. Management of breakthrough bleeding in patients with inhibitors on emicizumab involves episodic treatment with bypassing agents (BPA),… read more here.
Keywords: patients emicizumab; comparison bypassing; agents patients; bypassing agents ... See more keywords
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-056922
Abstract: Introduction Subcutaneous emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (PwHA) and factor VIII inhibitor. However, thrombotic events occurred in some PwHA with inhibitor who had received high cumulative doses of activated… read more here.
Keywords: unebi study; coagulation; bypassing agents; inhibitor ... See more keywords
Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th17-05-0365
Abstract: Patients with haemophilia and inhibitors to factors VIII or IX require bypassing therapy. The primary safety concern of bypassing agents is thromboembolism; however, the incidence of thromboembolic adverse events (TAEs) in haemophilia patients with inhibitors… read more here.
Keywords: use bypassing; patients haemophilia; haemophilia inhibitors; events per ... See more keywords